
Jon E Sprague

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7347973/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Uncoupling the agony from ecstasy. Nature, 2003, 426, 403-404.	13.7	133
2	Synthetic Cathinones ("Bath Saltsâ€). Journal of Emergency Medicine, 2014, 46, 632-642.	0.3	131
3	Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in an animal model*. Critical Care Medicine, 2005, 33, 1311-1316.	0.4	99
4	Hypothalamic-Pituitary-Thyroid Axis and Sympathetic Nervous System Involvement in Hyperthermia Induced by 3,4-Methylenedioxymethamphetamine (Ecstasy). Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 159-166.	1.3	82
5	Toxin-Induced Hyperthermic Syndromes. Medical Clinics of North America, 2005, 89, 1277-1296.	1.1	80
6	Hippocampal serotonergic damage induced by MDMA (ecstasy): effects on spatial learning. Physiology and Behavior, 2003, 79, 281-287.	1.0	78
7	The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. Journal of Molecular Medicine, 2004, 82, 787-799.	1.7	69
8	Community pharmacistsâ€~ attitudes towards clinical utility and ethical implications of pharmacogenetic testing. Personalized Medicine, 2013, 10, 793-800.	0.8	65
9	Roles of Norepinephrine, Free Fatty Acids, Thyroid Status, and Skeletal Muscle Uncoupling Protein 3 Expression in Sympathomimetic-Induced Thermogenesis. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 274-280.	1.3	52
10	The complementary and divergent roles of uncoupling proteins 1 and 3 in thermoregulation. Journal of Physiology, 2016, 594, 7455-7464.	1.3	51
11	The Pharmacology and Toxicology of the †Holy Trinity'. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 115-119.	1.2	48
12	Attenuation of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced rhabdomyolysis with α 1 - plus β 3 -adrenoreceptor antagonists. British Journal of Pharmacology, 2004, 142, 667-670.	2.7	45
13	UCP3 and thyroid hormone involvement in methamphetamine-induced hyperthermia. Biochemical Pharmacology, 2004, 68, 1339-1343.	2.0	40
14	In vivo microdialysis and conditioned place preference studies in rats are consistent with abuse potential of tramadol. Synapse, 2002, 43, 118-121.	0.6	36
15	Raman Spectroscopic Signature Markers of Dopamine–Human Dopamine Transporter Interaction in Living Cells. ACS Chemical Neuroscience, 2017, 8, 1510-1518.	1.7	27
16	Impact of common clandestine structural modifications on synthetic cathinone "bath salt― pharmacokinetics. Toxicology and Applied Pharmacology, 2017, 328, 18-24.	1.3	21
17	A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics. Psychopharmacology, 2019, 236, 881-890.	1.5	21
18	The hyperthermia mediated by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) is sensitive to sex differences. Toxicology and Applied Pharmacology, 2009, 235, 33-38.	1.3	19

JON E SPRAGUE

#	Article	IF	CITATIONS
19	The influence of the host microbiome on 3,4-methylenedioxymethamphetamine (MDMA)-induced hyperthermia and vice versa. Scientific Reports, 2019, 9, 4313.	1.6	19
20	During the COVID-19 Pandemic, Opioid Overdose Deaths Revert to Previous Record Levels in Ohio. Journal of Addiction Medicine, 2022, 16, e118-e122.	1.4	19
21	Impact of Functional Group Modifications on Designer Phenethylamine Induced Hyperthermia. Chemical Research in Toxicology, 2016, 29, 871-878.	1.7	17
22	Gender differences in tolerance to the hyperthermia mediated by the synthetic cathinone methylone. Temperature, 2019, 6, 334-340.	1.7	12
23	Cooling down the bath salts: Carvedilol attenuation of methylone and mephedrone mediated hyperthermia. Toxicology Letters, 2016, 263, 11-15.	0.4	10
24	PTSD Symptoms Experienced and Coping Tactics Used by Crime Scene Investigators in the United States. Journal of Forensic Sciences, 2019, 64, 1444-1450.	0.9	10
25	Drug safety assurance through clinical genotyping: near-term considerations for a system-wide implementation of personalized medicine. Personalized Medicine, 2008, 5, 387-397.	0.8	9
26	Body temperature regulation and drugs of abuse. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 157, 623-633.	1.0	8
27	Technical note: The effects of Bluestar® and luminol when used in conjunction with tetramethylbenzidine or phenolphthalein. Forensic Science International, 2016, 262, 156-159.	1.3	7
28	Pharmacodynamic characterization of insulin on MDMA-induced thermogenesis. European Journal of Pharmacology, 2009, 615, 257-261.	1.7	6
29	The "pharmacophore rule―and the "spices― Forensic Toxicology, 2015, 33, 170-173.	1.4	6
30	Fentanyl Detection Using Eosin Y Paper Assays,. Journal of Forensic Sciences, 2020, 65, 1432-1442.	0.9	5
31	Potential Contribution of the Intestinal Microbiome to Phenethylamine-Induced Hyperthermia. Brain, Behavior and Evolution, 2020, 95, 256-271.	0.9	5
32	COVID-19 economic impact payments and opioid overdose deaths. International Journal of Drug Policy, 2022, 102, 103608.	1.6	5
33	Potentiation of Ecstasy-induced hyperthermia and FAT/CD36 expression in chronically exercised animals. Temperature, 2016, 3, 557-566.	1.7	4
34	Stimulating and sustaining scholarly activity at teaching-intensive institutions. Currents in Pharmacy Teaching and Learning, 2021, 13, 228-237.	0.4	4
35	The pharmacodynamic characterization of an antisense oligonucleotide against monoamine oxidase-B (MAO-B) in rat brain striatal tissue. Cellular and Molecular Neurobiology, 2001, 21, 53-64.	1.7	3
36	The Effects of Ecstasy (MDMA) on Rat Liver Bioenergetics. Academic Emergency Medicine, 2004, 11, 723-729.	0.8	3

JON E SPRAGUE

#	Article	IF	CITATIONS
37	Reversal of temperature responses to methylone mediated through bi-directional fecal microbiota transplantation between hyperthermic tolerant and naÃ ⁻ ve rats. Temperature, 2022, 9, 318-330.	1.7	3
38	Systematic review of Pharmacogenomics Knowledgebase evidence for pharmacogenomic links to the dopamine reward pathway for heroin dependence. Pharmacogenomics, 2021, 22, 849-857.	0.6	2
39	Pharmacokinetic data of synthetic cathinones in female Sprague-Dawley rats. Data in Brief, 2018, 21, 1045-1050.	0.5	1
40	Construction of a Drug Safety Assurance Information System Based on Clinical Genotyping. , 2012, 2012, 1-9.		0
41	HealthCare educational differences in pain management, adverse childhood experiences and their relationship to substance use disorder education. Substance Abuse Treatment, Prevention, and Policy, 2022, 17, 10.	1.0	0
42	COVID-19 economic impact payments and opioid overdose deaths: A response. International Journal of Drug Policy, 2022, , 103767.	1.6	0